VR Logo

TransCode Therapeutics Inc. (RNAZ) download report


Healthcare | Biotechnology & Pharma Research

TransCode Therapeutics Inc. (RNAZ) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease.

IPO Date: 08-Jul-2021

Co-Founder, CEO, Pres & Director: Mr. Robert Michael Dudley

CFO, VP of Admin. & Director: Mr. Thomas A. Fitzgerald M.B.A.

Listing: NASDAQ: RNAZ

Country: United States

Headquarters: Boston, MA

Website: https://www.transcodetherapeutics.com

Key Facts

Market cap: $16.71 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-5.83 Mln

Cash: $16.85 Mln

Total Debt: $0.00 Mln

Insider's Holding: 32.62%

Liquidity: Low

52 Week range: $1.15 - 7.00

Shares outstanding: 12,977,200

Stock Performance

Time Period TransCode Therapeutics (RNAZ) S&P BSE Sensex* S&P Small-Cap 600*
YTD-50.39-8.99-19.22
1 month-31.15-3.40-9.34
3 months-53.85-8.50-14.58
1 Year--0.89-17.64
3 Years--10.415.91
5 Years--11.435.64
10 Years--11.7710.10
As on 29-Jun-2022 *As on 30-Jun-2022